News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oramed Pharmaceuticals Inc. (ORMP) To Present Results From Its Phase 2a FDA Trial With ORMD-0801 At The 2014 Diabetes Summit On April 24, 2014



3/3/2014 7:09:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JERUSALEM, March 3, 2014 /PRNewswire via COMTEX/ -- JERUSALEM, March 3, 2014 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (nasdaqcm:ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.

Help employers find you! Check out all the jobs and post your resume.

Read at Market Watch


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES